ReviewDiabetologia2018
Medication use for the treatment of diabetes in obese individuals.
Review in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.Journal of obesity · 2025Pooled it
- Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial.Clinical obesity · 2025Trial
- Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.Journal of diabetes investigation · 2023Trial
- Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1.The Journal of clinical endocrinology and metabolism · 2020Trial
- Various classification methods for diabetes mellitus in the management of blood glucose control.World journal of diabetes · 2025Article
- Safety and Effectiveness of Naltrexone-Bupropion in Korean Adults with Obesity: Post-Marketing Surveillance Study.Drug design, development and therapy · 2024Observational
- Benchmarking the medication efficiency and technological progress of diabetes drugs.Frontiers in public health · 2024Article
- Current and emerging medications for the management of obesity in adults.The Medical journal of Australia · 2023Review
- Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Article
- The association between overweight/obesity and double diabetes in adults with type 1 diabetes; a cross-sectional study.BMC endocrine disorders · 2021Article
- Article
- Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease.Journal of the Endocrine Society · 2020Article
- Effects of Self-Weighing During Weight Loss Treatment: A 6-Month Randomized Controlled Trial.Frontiers in psychology · 2020Article
- A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor.Frontiers in endocrinology · 2020Article
- Effect of mushrooms on obesity in animal models: study protocol for a systematic review and meta-analysis.Systematic reviews · 2019Article
- Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study.Endocrinology, diabetes & metabolism · 2019Article
- Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence.World journal of diabetes · 2019Review
- Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes.BMJ open diabetes research & care · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major cause of type 2 diabetes and may complicate type 1 diabetes. Weight loss for obese individuals with diabetes has many health benefits, often leads to improvement in glucose control and sometimes, in type 2 diabetes, near normalisation of abnormal glucose metabolism. Weight loss is difficult to maintain and attempts to lose weight may be undermined by some diabetes treatments such as sulfonylureas, thiazolidinediones and insulin. Whilst lifestyle support should be the primary approach to aid individuals who wish to lose weight, pharmacological approaches can also be considered. These include choosing glucose-lowering drugs or drug combinations that are weight neutral or result in weight loss or prescribing drugs that are specifically approved as anti-obesity medication. Given that some of the newer glucose-lowering medications that cause weight loss, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), are also being used or considered for use as anti-obesity drugs, it seems that the distinction between glucose-lowering medication and weight loss medication is becoming blurred. This review discusses the main pharmacological approaches that can be used to support weight loss in individuals with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.